


Journal of International Oncology››2024,Vol. 51››Issue (12): 779-784.doi:10.3760/cma.j.cn371439-20240727-00132
• Reviews •Previous ArticlesNext Articles
Zhou Mingrui1, Qi Mengqi2, Zhang Yanyan1, Shi Yinuan1, Yue Chuan1, Zhang Yan1, Liu Xianqiang1, Zhang Yan1(
)
Received:2024-07-27Revised:2024-09-01Online:2024-12-08Published:2025-01-07Contact:Zhang Yan E-mail:285951758@qq.comZhou Mingrui, Qi Mengqi, Zhang Yanyan, Shi Yinuan, Yue Chuan, Zhang Yan, Liu Xianqiang, Zhang Yan. Research progress in the relationship between microbial communities and breast cancer in human tissues[J]. Journal of International Oncology, 2024, 51(12): 779-784.
| [1] | Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3): 229-263. DOI:10.3322/caac.21834. |
| [2] | Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J].CA Cancer J Clin,2024,74(1): 12-49. DOI:10.3322/caac.21820. |
| [3] | Sukumar J, Kassem M, Agnese D, et al. Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series[J].Breast Cancer Res Treat,2021,186(2): 569-575. DOI:10.1007/s10549-021-06095-w. |
| [4] | Schluter J, Peled JU, Taylor BP, et al. The gut microbiota is associated with immune cell dynamics in humans[J].Nature,2020,588(7837): 303-307. DOI:10.1038/s41586-020-2971-8. |
| [5] | Wu Y, Zhang Y, Zhang W, et al. The tremendous clinical potential of the microbiota in the treatment of breast cancer: the next frontier[J].J Cancer Res Clin Oncol,2023,149(13): 12513-12534. DOI:10.1007/s00432-023-05014-4. pmid:37382675 |
| [6] | Bernardo G, Le Noci V, Di Modica M, et al. The emerging role of the microbiota in breast cancer progression[J].Cells,2023,12(15): 1945. DOI:10.3390/cells12151945. |
| [7] | Perler BK, Friedman ES, Wu GD. The role of the gut microbiota in the relationship between diet and human health[J].Annu Rev Physiol,2023,85: 449-468. DOI:10.1146/annurev-physiol-031522-092054. |
| [8] | Ahn J, Hayes RB. Environmental influences on the human microbiome and implications for noncommunicable disease[J].Annu Rev Public Health,2021,42: 277-292. DOI:10.1146/annurev-publhealth-012420-105020. |
| [9] | Wu AH, Tseng C, Vigen C, et al. Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study[J].Breast Cancer Res Treat,2020,182(2): 451-463. DOI:10.1007/s10549-020-05702-6. |
| [10] | Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria[J].Science,2020,368(6494): 973-980. DOI:10.1126/science.aay9189. pmid:32467386 |
| [11] | Wang N, Sun T, Xu J. Tumor-related microbiome in the breast microenvironment and breast cancer[J].J Cancer,2021,12(16): 4841-4848. DOI:10.7150/jca.58986. pmid:34234854 |
| [12] | Gomaa EZ. Human gut microbiota/microbiome in health and diseases: a review[J].Antonie Van Leeuwenhoek,2020,113(12): 2019-2040. DOI:10.1007/s10482-020-01474-7. |
| [13] | Song X, Wei C, Li X. The relationship between microbial community and breast cancer[J].Front Cell Infect Microbiol,2022,12: 849022. DOI:10.3389/fcimb.2022.849022. |
| [14] | Zhang Z, Tang H, Chen P, et al. Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome[J].Signal Transduct Target Ther,2019,4: 41. DOI:10.1038/s41392-019-0074-5. |
| [15] | Komorowski AS, Pezo RC. Untapped "-omics": the microbial metagenome, estrobolome, and their influence on the development of breast cancer and response to treatment[J].Breast Cancer Res Treat,2020,179(2): 287-300. DOI:10.1007/s10549-019-05472-w. |
| [16] | Wu Z, Pfeiffer RM, Byrd DA, et al. Associations of circulating estrogens and estrogen metabolites with fecal and oral microbiome in postmenopausal women in the Ghana breast health study[J].Microbiol Spectr,2023,11(4): e0157223. DOI:10.1128/spectrum.01572-23. |
| [17] | Simin J, Tamimi RM, Engstrand L, et al. Antibiotic use and the risk of breast cancer: a systematic review and dose-response Meta-analysis[J].Pharmacol Res,2020,160: 105072. DOI:10.1016/j.phrs.2020.105072. |
| [18] | Xiao L, Chi D, Sheng G, et al. Inhibitory effects of UDP-glucuronosyltransferase(UGT) typical ligands against E. coli beta-glucuronidase(GUS)[J].RSC Adv,2020,10(39): 22966-22971. DOI:10.1039/d0ra02311f. |
| [19] | Munteanu C, Schwartz B. Interactions between dietary antioxidants, dietary fiber and the gut microbiome: their putative role in inflammation and cancer[J].Int J Mol Sci,2024,25(15): 8250. DOI:10.3390/ijms25158250. |
| [20] | Nakatsu G, Andreeva N, MacDonald MH, et al. Interactions between diet and gut microbiota in cancer[J].Nat Microbiol,2024,9(7): 1644-1654. DOI:10.1038/s41564-024-01736-4. |
| [21] | Arnone AA, Wilson AS, Soto-Pantoja DR, et al. Diet modulates the gut microbiome, metabolism, and mammary gland inflammation to influence breast cancer risk[J].Cancer Prev Res (Phila),2024,17(9): 415-428. DOI:10.1158/1940-6207.CAPR-24-0055. |
| [22] | Dutta RK, Abu YF, Tao J, et al. Altered gut microbiome drives heightened pain sensitivity in a murine model of metastatic triple-negative breast cancer[J].Am J Cancer Res,2024,14(1): 274-299. DOI:10.62347/LUJF9626. pmid:38323292 |
| [23] | Gur C, Maalouf N, Shhadeh A, et al. Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1[J].Oncoimmunology,2019,8(6): e1581531. DOI:10.1080/2162402X.2019.1581531. |
| [24] | Dohrn G. Gut microbes linked to fatty diet drive tumour growth[J].Nature,2024, In press. DOI:10.1038/d41586-024-01443-4. |
| [25] | Sampsell K, Hao D, Reimer RA. The gut microbiota: a potential gateway to improved health outcomes in breast cancer treatment and survivorship[J].Int J Mol Sci,2020,21(23): 9239. DOI:10.3390/ijms21239239. |
| [26] | Raza MH, Gul K, Arshad A, et al. Microbiota in cancer development and treatment[J].J Cancer Res Clin Oncol,2019,145(1): 49-63. DOI:10.1007/s00432-018-2816-0. pmid:30542789 |
| [27] | Eslami-S Z, Majidzadeh-A K, Halvaei S, et al. Microbiome and breast cancer: new role for an ancient population[J].Front Oncol,2020,10: 120. DOI:10.3389/fonc.2020.00120. pmid:32117767 |
| [28] | Jaye K, Li CG, Chang D, et al. The role of key gut microbial metabolites in the development and treatment of cancer[J].Gut Microbes,2022,14(1): 2038865. DOI:10.1080/19490976.2022.2038865. |
| [29] | Su X, Gao Y, Yang R. Gut microbiota derived bile acid metabolites maintain the homeostasis of gut and systemic immunity[J].Front Immunol,2023,14: 1127743. DOI:10.3389/fimmu.2023.1127743. |
| [30] | Urbaniak C, Gloor GB, Brackstone M, et al. The microbiota of breast tissue and its association with breast cancer[J].Appl Environ Microbiol,2016,82(16): 5039-5048. DOI:10.1128/AEM.01235-16. |
| [31] | Meng Z, Ye Z, Zhu P, et al. New developments and opportunities of microbiota in treating breast cancers[J].Front Microbiol,2022,13: 818793. DOI:10.3389/fmicb.2022.818793. |
| [32] | Wong CC, Yu J. Gut microbiota in colorectal cancer development and therapy[J].Nat Rev Clin Oncol,2023,20(7): 429-452. DOI:10.1038/s41571-023-00766-x. pmid:37169888 |
| [33] | Zhang YX, Liang ZZ, Li YQ, et al. Association between weight change and breast cancer prognosis[J].Breast Cancer Res Treat,2022,193(3): 677-684. DOI:10.1007/s10549-022-06592-6. |
| [34] | Summer M, Sajjad A, Ali S, et al. Exploring the underlying correlation between microbiota, immune system, hormones, and inflammation with breast cancer and the role of probiotics, prebiotics and postbiotics[J].Arch Microbiol,2024,206(4): 145. DOI:10.1007/s00203-024-03868-x. |
| [35] | Ma C, Wasti S, Huang S, et al. The gut microbiome stability is altered by probiotic ingestion and improved by the continuous supplementation of galactooligosaccharide[J].Gut Microbes,2020,12(1): 1785252. DOI:10.1080/19490976.2020.1785252. |
| [36] | Mendoza L. Potential effect of probiotics in the treatment of breast cancer[J].Oncol Rev,2019,13(2): 422. DOI:10.4081/oncol.2019.422. |
| [37] | Vincenzi A, Goettert MI, Volken de Souza CF. An evaluation of the effects of probiotics on tumoral necrosis factor (TNF-α) signa-ling and gene expression[J].Cytokine Growth Factor Rev,2021,57: 27-38. DOI:10.1016/j.cytogfr.2020.10.004. |
| [38] | Perales-Puchalt A, Perez-Sanz J, Payne KK, et al. Frontline science: microbiota reconstitution restores intestinal integrity after cisplatin therapy[J].J Leukoc Biol,2018,103(5): 799-805. DOI:10.1002/JLB.5HI1117-446RR. |
| [39] | Fessler J, Matson V, Gajewski TF. Exploring the emerging role of the microbiome in cancer immunotherapy[J].J Immunother Cancer,2019,7(1): 108. DOI:10.1186/s40425-019-0574-4. |
| [40] | Vafa S, Zarrati M, Malakootinejad M, et al. Calorie restriction and synbiotics effect on quality of life and edema reduction in breast cancer-related lymphedema, a clinical trial[J].Breast,2020,54: 37-45. DOI:10.1016/j.breast.2020.08.008. pmid:32898787 |
| [41] | Thet D, Areepium N, Siritientong T. Effects of probiotics on chemotherapy-induced diarrhea[J].Nutr Cancer,2023,75(10): 1811-1821. DOI:10.1080/01635581.2023.2267779. |
| [42] | Shiao SL, Kershaw KM, Limon JJ, et al. Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy[J].Cancer Cell,2021,39(9): 1202-1213, e6. DOI:10.1016/j.ccell.2021.07.002. pmid:34329585 |
| [43] | Juan Z, Chen J, Ding B, et al. Probiotic supplement attenuates chemotherapy-related cognitive impairment in patients with breast cancer: a randomised, double-blind, and placebo-controlled trial[J].Eur J Cancer,2022,161: 10-22. DOI:10.1016/j.ejca.2021.11.006. pmid:34896904 |
| [44] | Mirzadeh MA, Eslami M, Ghanbari A, et al. Coadministration of doxorubicin with vitamin D3, Lactobacillus acidophilus, and Lactobacillus casei in the 4T1 mouse model of breast cancer: anticancer and enteroprotective effects[J].Med Oncol,2024,41(5): 111. DOI:10.1007/s12032-024-02346-0. |
| [45] | Federici S, Kredo-Russo S, Valdés-Mas R, et al. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation[J].Cell,2022,185(16): 2879-2898, e24. DOI:10.1016/j.cell.2022.07.003. pmid:35931020 |
| [46] | Álvarez-Mercado AI, Del Valle Cano A, Fernández MF, et al. Gut microbiota and breast cancer: the dual role of microbes[J].Cancers (Basel),2023,15(2): 443. DOI:10.3390/cancers15020443. |
| [47] | Yi DY, Kim SY. Human breast milk composition and function in human health: from nutritional components to microbiome and microRNAs[J].Nutrients,2021,13(9): 3094. DOI:10.3390/nu13093094. |
| [48] | Parida S, Wu S, Siddharth S, et al. A procarcinogenic colon microbe promotes breast tumorigenesis and metastatic progression and concomitantly activates notch and β-catenin axes[J].Cancer Discov,2021,11(5): 1138-1157. DOI:10.1158/2159-8290.CD-20-0537. pmid:33408241 |
| [49] | Parhi L, Alon-Maimon T, Sol A, et al. Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression[J].Nat Commun,2020,11(1): 3259. DOI:10.1038/s41467-020-16967-2. |
| [50] | Devoy C, Flores Bueso Y, Tangney M. Understanding and harnessing triple-negative breast cancer-related microbiota in oncology[J].Front Oncol,2022,12: 1020121. DOI:10.3389/fonc.2022.1020121. |
| [51] | Bose D, Banerjee S, Singh RK, et al. Vascular endothelial growth factor encoded by Parapoxviruses can regulate metabolism and survival of triple negative breast cancer cells[J].Cell Death Dis,2020,11(11): 996. DOI:10.1038/s41419-020-03203-4. |
| [52] | Banerjee S, Wei Z, Tian T, et al. Prognostic correlations with the microbiome of breast cancer subtypes[J].Cell Death Dis,2021,12(9): 831. DOI:10.1038/s41419-021-04092-x. |
| [53] | Zhang Y, Zhou M, Sun J. A novel prognostic signature and potential therapeutic drugs based on tumor immune microenvironment characterization in breast cancer[J].Heliyon,2023,9(10): e20798. DOI:10.1016/j.heliyon.2023.e20798. |
| [54] | Naderi N, Mosahebi A, Williams NR. Microorganisms and breast cancer: an in-depth analysis of clinical studies[J].Pathogens,2023,13(1): 6. DOI:10.3390/pathogens13010006. |
| [1] | Han Xiaoxu, Zhang Nan, Liu Shuai.Progress in the study of the pregnane X receptor in drug resistance in breast cancer[J]. Journal of International Oncology, 2024, 51(9): 590-594. |
| [2] | Zhao Biao, Pu Qin, Yuan Meifang, Ma Lishuang, Li Han, Yang Yi, Sun Chaoxi.Dosimetric study of intensity-modulated radiotherapy and volumetric intensity modulated arc therapy based on the inner edge tangent field for radiotherapy after breast-conserving surgery of left-sided breast cancer[J]. Journal of International Oncology, 2024, 51(7): 441-447. |
| [3] | Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369. |
| [4] | Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375. |
| [5] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381. |
| [6] | Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234. |
| [7] | Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238. |
| [8] | Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82. |
| [9] | Tan Shuangxiu, Zhang Yidan, Wang Ying, Yu Pengli, Kong Wentao, Yao Jing, Chen Qiaoliang.Value of conventional ultrasound combined with shear wave elastography in differentiating non-mass ductal carcinomain situfrom invasive breast cancer[J]. Journal of International Oncology, 2024, 51(12): 743-748. |
| [10] | Wang Li, Xiao Han, Huang Guofu.Mechanism of action and clinical significance of circular RNA in triple negative breast cancer[J]. Journal of International Oncology, 2024, 51(12): 774-778. |
| [11] | Zhu Bin, Wan Tao, Xu Hua, Jia Hao, Chen Shixin.Value analysis of the prediction model based on multimodal MRI characteristics for the differential diagnosis of benign and malignant BI-RADS 4 types of breast tumors[J]. Journal of International Oncology, 2024, 51(11): 678-683. |
| [12] | Chen Kunyan, Du Juan, Ji Yuwei, Gu Weiwei, Peng Hanzhi.Effects of irinotecan combined with XELOX regimen on immune status, intestinal microecology and prognostic risk in elderly patients with colorectal cancer[J]. Journal of International Oncology, 2024, 51(11): 690-695. |
| [13] | Tao Jin, Kan Junnan, Yang Caixia, Liu Yan, Lyu Yijie, Wei Junhui, Li Xianglin.Progress of manganese-based nanomaterials in breast cancer diagnosis and treatment[J]. Journal of International Oncology, 2024, 51(10): 645-649. |
| [14] | Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer: present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58. |
| [15] | Wang Jing, Xu Wenting.Value of NLR, CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526. |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||